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PHARMACY ISSUES
TPP1
IMPLEMENTING A MODEL OF RISK SHARING
OF PHARMACEUTICAL BENEFITS IN 
PRIMARY CARE
Gilabert A, Casals A, Sedano E
Catalan Health Service, Autonomous Government of 
Catalonia, Barcelona, Spain
OBJECTIVE: To design and assess a model of risk shar-
ing of pharmaceutical benefits in primary care based on
allocating prescription budgets, assigning prescription
quality standards and linking the results to an economi-
cal benefit.
METHODOLOGY: In 1998 a prescribing budget was as-
signed to primary health care teams (PHCTs) of 22 basic
health areas (BHAs) (488,900 inhabitants). The methodol-
ogy for allocating drug budgets was based on the calcula-
tion of a maximum expenditure permitted (MEP) for each
PHCT by assigning a percent increase above the previous
year’s expenditure, proportionally inverse to its cost/inhab-
itant. This cost/inhabitant was modulated by the percentage
of population with free pharmaceutical coverage (popula-
tion 65 years old or over and other specific population
groups ) and the typology of the BHA (urban or rural). Pre-
scribing quality standards (PQS) assigned for each PHCT
consisted of the intrinsic pharmacological value (IPhV) of
the prescription and the defined daily doses per 1,000 inhab-
itants per year (DHD) for anti-bacterial drugs and NSAIDs.
Values for qualitative indicators were assigned depending
on the distance between the PHCT’s current value and the
group average. Non-achievement of the objectives assigned
for both MEPs and PQSs was linked to a loss of 2% of the
total budget allocation contracted with the PHCT.
RESULTS: The assesment of the prescribing budget ob-
jective showed that 36.4% of PCHTs had an expenditure
below its MEPs and 63.6% over. Of PHCTs exceeding
MEP, 42.9% presented a deviation of less than 5%,
28.6% between 5–10%, 21.4% between 10–15% and
7.1% greater than 15%. Qualitative evaluation showed
that 86.4% of PHCTs achieved the objective of IPhV,
81.8% reached the DHD assigned for anti-bacterials and
68% the DHD for NSAIDs.
CONCLUSION: The model has permitted the Catalan
Health Service to implement the concept of risk sharing
in the management of pharmaceutical benefits in primary
care, and the introduction of greater accountability for
prescription costs in general practice.
TPP2
EVALUATION OF A THERAPEUTIC 
INTERCHANGE PROGRAM FOR CALCIUM 
CHANNEL BLOCKERS IN HYPERTENSION
Nichol MB1, Harada ASM1, Jones J1, Gilderman A2, Salas J2
1University of Southern California, Los Angeles, CA, USA; 
2Prescription Solutions, Costa Mesa, CA, USA
OBJECTIVES: This project evaluated a therapeutic inter-
change program of a pharmacy benefit management firm
that initiated an amlodipine to felodipine therapeutic in-
terchange program. The purpose of this study was to in-
vestigate the effect of switching hypertension therapy in a
group of managed care patients on health-related quality
of life, patient satisfaction, and prescription utilization
and cost.
METHOD: Three groups of managed care patients were
prospectively selected from five large primary care medi-
cal groups in Texas and Oklahoma during the last six
months of 1997. A study group of patients undergoing
interchange (switching from amlodipine to felodipine),
and two comparison groups of patients not undergoing a
medication change were used (continuous amlodipine
and continuous felodipine). Baseline (before a planned
interchange) patient questionnaires were mailed to a total
of 802 patients (Groups 1–3) and eight-week follow-up
(after the interchange) patient questionnaires were mailed
to 295 patients who responded to the first survey. The
patient questionnaires included the SF-36, symptom mea-
sures, and satisfaction with care. Prescription claims data
were used for the utilization and cost analysis.
RESULTS: Patients maintaining therapy on felodipine
continuously were older than amlodipine or switched pa-
tients and were more likely to be female. Switch patients
had lower total prescription utilization after the switch
compared to the continuous-use groups. Switch patients
also had fewer hypertension-related prescriptions after
the switch. There were no statistically significant differ-
ences in quality of life. It appeared that switch patients
were more likely to change hypertension medications af-
ter their initial switch.
CONCLUSIONS: The clear difference in patient charac-
teristics between the treatment groups implies an impor-
tant selection bias. These differences may mean that pa-
tients subject to the therapeutic interchange were selected
for clinical or other reasons not immediately apparent.
Subsequent analyses should control for these effects.
TPP3
PHARMACEUTICAL CARE AND HEALTH
CARE UTILIZATION
Fischer LR, DeFor T, Cooper S, Scott L, Boonstra D, 
Eelkema M, Hase K, Goodman M
HealthPartners, Minneapolis, MN, USA
OBJECTIVES: To assess if pharmaceutical care is associ-
ated with a decrease in overall health care utilization and
cost. Pharmaceutical care entails an expanded role for
pharmacists to provide patient counseling and monitoring
about medications. Few adequately designed studies have
investigated the impact on health care utilization, and, to
date, findings are mixed.
METHODS: A quasi-experimental design, using utiliza-
tion/cost data from an HMO database. Intervention sites
were 3 staff and 3 contract pharmacies. HMO enrollees
with chronic health conditions (lung or heart disease) were
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identified through the HMO’s electronic pharmacy data-
base. Two years of utilization data (Year-Before and Year-
After intervention) were extracted from the HMO database
for participants, refusers and controls, excluding people
who died, disenrolled, or discontinued their pharmacy
benefit. Multiple linear regression analyses were per-
formed with the following dependent variables: difference
between Year-Before and Year-After in number of clinic
visits, prescriptions dispensed, unique medications, hospi-
tal admits, and hospital days, as well as inpatient, outpa-
tient, and total charges. Separate regression analyses were
run for 2 models: participants vs. controls and interven-
tion [participants  refusers] vs. controls. Other variables
in the regression models were gender, age, Charlson Co-
morbidity Index in Year-Before, and group (lung vs. heart
disease).
RESULTS: Participants were more likely than controls to
have an increase in both clinic visits (on average, 1.8 more
visits) and prescriptions filled (2.4 more fills). Those in the
intervention sample (participants  refusers) were also
somewhat more likely than controls to increase their num-
bers of unique medications (0.6 more). None of the other
regression models were significant for the main predictor
variables.
CONCLUSIONS: Our study does not find that pharma-
ceutical care decreases health care utilization or cost in this
HMO setting. To the contrary, pharmaceutical care ap-
pears to be associated with an increase in utilization.
TPP4
POTENTIAL COST SAVINGS BY PRESCRIPTION 
OF THE CHEAPEST DRUGS AMONG THOSE 
WITH EQUAL CONTENT IN PRIMARY CARE
Alegre de Rey E, Martinez Rodriguez L, Rabadan Asensio A
Pharmacy Unit, Cadiz-Bahia Primary Care Area, Cadiz, Spain
OBJECTIVES: To calculate the cost savings if the cheapest
trade marks were prescribed. Competence among drug
companies has contributed to a rising potential of saving,
so making possible a more efficient use of drugs.
METHODS: We take a database with every prescription
made in 1998 by a staff of 239 health-system physicians in
Cádiz-Bahía Primary Care Area. This Area has 468,908 in-
habitants. The study was done by taking a sample of those
drugs with more potential of cost saving: 6 antiulcer drugs,
10 antibiotics, 8 antihypertensive and 9 NSAIDs.
RESULTS: The real cost of prescription of these drugs in
1998 was 3.583.500E. 790.841E (28,8%) could be saved
if cheaper trade marks were prescribed. That proportion
was similar among anti-hypertensives (30,5%) NSAIDs
(29,5%), antiulcer drugs (29,4%) and antibiotics (24,5%),
but potential savings were greater for antihypertensives
(414.762E) than for antiulcer drugs (232.573E), antibiot-
ics (196.297E) or NSAIDs (187.265E). Related to specific
drugs, 10 drugs get more than 80% of potential savings,
and only 4 get more than 50%. They are enalapril
(23,5%, 268919E), omeprazol (12%, 138.000E), captopril
(10,2%, 116.724 E), ibuprofen (8,2%, 93.459E). Among
antibiotics, we could reach 79% of potential savings with
ciprofloxacin and amoxicillin/clavulanate. 93% of poten-
tial cost savings in antihypertensives could be reached with
enalapril and captopril. With omeprazole only we could
reach 59% of savings in antiulcer drugs. There are not
such differences among NSAIDs.
CONCLUSIONS: A great proportion (25–30%) of costs
could be saved if the physician knows and prescribes the
cheapest alternatives among those with equal content. Spe-
cial attention is needed about potential cost savings of few
drugs.
ECONOMIC MODELING STUDY ISSUES
TPE1
ASSESSMENT OF THE APPROPRIATENESS OF 
CLINICAL GUIDELINES FOR CONTINUATION 
TREATMENT IN MAJOR DEPRESSION FROM A 
HEALTH ECONOMIC PERSPECTIVE
Nuijten MJC
MEDTAP International, Amsterdam, The Netherlands
OBJECTIVE: The primary objective of this study was to
assess the appropriateness of the existing Dutch guidelines
(“NHG-standard”) from a health economic perspective.
Those guidelines recommend continuation treatment for pe-
riod of 6 months. We also assessed additional maintenance
treatment for 1 year after the continuation period.
METHODS: The assessment was based on a Markov
model based on decision analytic techniques. For this analy-
sis we defined 3 mutually exclusive states: no depression
(ND), depression with treatment in ambulatory setting
(DA), depression/treatment failure requiring hospitalization
(DH). The outcomes for the model have been defined as:
QALYs and direct medical, while the study was performed
from the health insurance perspective in The Netherlands in
1999. The probabilities of clinical events and therapeutic
choices as well as the utilities were based on published liter-
ature. The medical resource use related to each state was ab-
stracted from published literature and expert opinion. The
associated 1999 unit costs of the used medical resources
were derived from official Dutch tariff lists.
RESULTS: The results of the baseline analysis showed that
a treatment according to the guidelines will result in an in-
cremental cost-effectiveness ratio of 81,700 NLG per
QALY. Treatment according to the guidelines increased the
total costs from NLG 49 to NLG 683, while the number of
QALYs increased from 0.45 to 0.47. Sensitivity analyses
confirmed the robustness of these findings. Extension of
treatment to maintenance treatment (6 months and 12
months) reduced the incremental cost-effectiveness ratio to
only 12,330 NLG per QALY.
CONCLUSION: In conclusion, based on the assumptions
used in the model, the Dutch clinical guidelines for depres-
sion are appropriate from a health economic perspective,
when they are extended to beyond continuation period until
maintenance treatment.
